Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420111 | 0.79 | RAD51 (0.48) | RAD51 | |
| SCHEMBL4848548 | 0.69 | CASP3 (0.31) | — | |
| SCHEMBL1163642 | 0.68 | GSK3A (0.35) | — | |
| SCHEMBL23974872 | 0.63 | — | — | |
| SCHEMBL12360481 | 0.61 | BRD4 (0.39) | — | |
| SCHEMBL68353 | 0.61 | — | — | |
| SCHEMBL11028940 | 0.61 | MAOA (0.40) | — | |
| SCHEMBL12804690 | 0.59 | GRIN2D (0.59) | — | |
| SCHEMBL30454486 | 0.59 | GRIN2D (0.59) | — | |
| Hydrochloric Acid SCHEMBL2171904 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | disclosed |
| US-8933074-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933074-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933074-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2297133-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | RAD51 3257/4885 |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | RAD51 3257/4885 |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | RAD51 3257/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | RAD51 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.